ERBB2 and neoplasm: Only 3% of tumours from patients with eCCA and 8% of ampullary tumours were identified to have a HER-2 (Figure 3B; Tables S2 and S4) and HER-3 alterations (Figure 3C; Tables S2 and S6), respectively.